Ferring announced a research collaboration with the Chinese Academy of Sciences

12 January 2018

GMP News

Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic strategies.

As part of the agreement, a new jointly funded laboratory will be created within the CAS research facility in Beijing, China. Known as the ‘Ferring Institute of Reproductive Medicine’, the facility will bring together researchers from both Ferring and CAS to find solutions to address global challenges in fertility and high rates of obstetric complications.

“Across the world, too many couples still face considerable challenges when trying to become families,” said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals. “This collaboration forms the next phase in our ongoing efforts to advance knowledge and care in reproductive medicine and women’s health. Working together we hope to gain a deeper understanding of fertility and implantation and discover new solutions that could transform the way in which reproductive medicine is managed in the future.”

For CAS, the collaboration will provide additional expertise and funding to support their world-class stem cell research and regenerative medicine programme, a core element of their Innovation 2030: Building Tomorrow initiative. For Ferring, the collaboration will help to identify new therapeutic concepts and targets that will enable the discovery of novel drug candidates that may be further developed to address unmet needs in reproductive medicine and women’s health.

“CAS is already recognised as a leading life science institute for our early basic research in reproductive biology, which covers most aspects of female and male infertility and obstetric complications,” said Prof Qi Zhou, Director of the Institute of Stem Cell and Regeneration and the Institute of Zoology, Chinese Academy of Sciences.

Previous publication Next publication

Media Center

  • 22 March 2018

    GMP Inspection practice: a case for global benchmarking, convergence and mutual reliance/recognition

    In 1969 the global agreement on the Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce was proposed by WHO. The aim was to facilitate international trade in pharmaceuticals through mutual recognition of GMP inspection results. Today, almost 50 years later, up to one hundred countries conduct foreign inspections. As a result a manufacturing site well established, might be inspected  many times in one year by local and different foreign authorities. This leads to duplication of work and waste of recourses both by regulators and industry.

  • 22 March 2018

    Kaluga is expected to complete its program for radiopharmaceuticals in two years

    Kaluga pharmaceutical cluster recently increased the number of locally manufactured drugs from 65 to 154. The Governor Anatoly Artamonov expects that the region needs 2 more years to complete its import substitution program for radiopharmaceuticals, reported Kaluzhskaya Nedelya, a local newspaper.

  • 21 March 2018

    Blockchain technology has a special potential to confront counterfeit drugs

    DHL has released a trend report in cooperation with Accenture, a leading global technology consultant, on blockchain technology’s potential to transform the logistics industry. The report includes initial findings on a working prototype developed by DHL and Accenture, which tracks pharmaceuticals from the point of origin to the consumer, preventing tampering and errors.

  • 20 March 2018

    Russia establishes its National Quality Infrastructure Council

    On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products. The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

Read more